HER2 Non-Small Cell Lung Cancer Epidemiology Forecast 2025-2034

HER2 non-small cell lung cancer refers to a type of lung cancer where the tumor cells express high levels of the HER2 protein. Nearly 50% to 75% of females are more prone to HER2-mutated NSCLC, indicating a high occurrence of HER2 non-small cell lung cancer (NSCLC) in females rather than in males. The HER2 non-small cell lung cancer (NSCLC) epidemiology forecast suggests an increasing recognition of HER2 alterations in NSCLC, with variations across different populations.

HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report Coverage

The “HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of HER2 non-small cell lung cancer. It projects the future incidence and prevalence rates of HER2 non-small cell lung cancer cases across various populations. The study covers age and type as major determinants of the HER2 non-small cell lung cancer population. The report highlights patterns in the prevalence of HER2 non-small cell lung cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on HER2 non-small cell lung cancer epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

HER2 Non-Small Cell Lung Cancer Understanding: Disease Overview

HER2 non-small cell lung cancer (NSCLC) is a rare type of lung cancer. It happens when there are changes in the HER2 gene. These changes can include mutations, amplifications, or too much HER2 protein. HER2 alterations are more common in people who have never smoked and in Asian populations.

Most HER2 non-small cell lung cancer cases are a type of NSCLC called adenocarcinoma. HER2 changes usually don’t occur with other common mutations like EGFR or ALK, which are also known to drive lung cancer. It is important for patients to have molecular testing to check for HER2 and other mutations before starting HER2 non-small cell lung cancer treatment.

HER2 Non-Small Cell Lung Cancer Epidemiology Perspective

The HER2 non-small cell lung cancer epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the HER2 non-small cell lung cancer epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for HER2 Non-Small Cell Lung Cancer and their trends. The HER2 non-small cell lung cancer detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the Translational Lung Cancer Research's recent studies on HER2 mutations, non-small cell lung cancer was reported mostly in Asian patient populations, where the percentage of lung cancer patients who have never smoked is higher by about 30 % than in North American and European populations, at 10%.
• Patients with adenocarcinoma non-small cell lung cancer who have little to no history of smoking are more likely to have HER2 mutations. HER2 mutations are found in about 2 % of patients with lung cancer.
• According to an article published in ScienceDirect, patients with HER2 non-small cell lung cancer usually have a median age of 65 years.
• The human epidermal growth factor receptor 2 (HER2) gene is overexpressed or mutated in HER2-positive non-small cell lung cancer (NSCLC), a subtype of lung cancer. These changes, which cause unchecked cell growth, occur in about 1% to 3% of non-small cell lung cancer cases. Nonsmokers and people with adenocarcinoma histology are more likely to have HER2 mutations.

Country-wise HER2 Non-Small Cell Lung Cancer Epidemiology Segment

The HER2 non-small cell lung cancer epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of HER2 non-small cell lung cancer varies significantly between countries due to differences in factors such as hygiene practices and genetic factors, among others. In the United States, 1-6 .7% of cases of non-small cell lung cancer (NSCLC) have HER2 alterations. HER2 mutation, amplification, and overexpression are among these changes.

HER2 Non-Small Cell Lung Cancer Treatment Overview

Targeted therapies that specifically target HER2 alterations are part of the treatment for HER2 non-small cell lung cancer (NSCLC). In patients with HER2 mutations, the antibody-drug conjugate trastuzumab deruxtecan has shown notable effectiveness. Tyrosine kinase inhibitors (such as neratinib and poziotinib) and chemotherapy are additional HER2 non-small cell lung cancer therapeutics for more comprehensive disease control.

Although its effectiveness in HER2-positive cases is still being investigated, immunotherapy may also be taken into consideration. The type of HER2 alteration, the cancer's stage, and the patient's general health are some of the factors that go into choosing a HER2 non-small cell lung cancer treatment. Clinical trials are still a crucial tool for investigating new treatments. Patients with this aggressive cancer type now have more options than chemotherapy thanks to targeted therapies like HER2 inhibitors.

Key Questions Answered

• What are the key findings of HER2 non-small cell lung cancer epidemiology in the 8 major markets?
• What will be the total number of patients with HER2 non-small cell lung cancer across the 8 major markets during the forecast period?
• What was the country-wise HER2 non-small cell lung cancer epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of HER2 non-small cell lung cancer cases during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of HER2 non-small cell lung cancer during the forecast period of 2025-2034?
• What are the currently available treatments in the global HER2 non-small cell lung cancer market?
• What are the disease risks, signs, symptoms, and unmet needs of HER2 non-small cell lung cancer?

Scope of the HER2 Non-Small Cell Lung Cancer Epidemiology Report

• The HER2 non-small cell lung cancer epidemiology forecast covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of HER2 Non-Small Cell Lung Cancer based on several factors.
• The HER2 Non-Small Cell Lung Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The HER2 non-small cell lung cancer report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.